MyFinsight
Home
Blog
About
ImageneBio, Inc. (IMA)
ImageneBio, Inc. (IMA)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Stock-based compensation expense
Amortization of right of use-ass...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Net loss
Deposits and other non-current a...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
Non-cash interest expense
-
0
489
Net loss
-10,619
-6,908
-38,441
Stock-based compensation expense
876
51
15,340
Amortization of right of use-assets
174
168
466
Gain on early extinguishment of lease liability
-
0
149
Accretion of discounts on marketable securities, net
7
38
33
Loss on disposal of property and equipment
-
0
0
Non-cash interest expense
0
-
-
Non-cash research and development expenses for the common stock issuable pursuant to hutchmed agreement
-
0
0
Depreciation and amortization expense
0
393
6
Prepaid expenses and other current assets
-141
383
3,574
Other non-current assets
-
-72
1,277
Deposits and other non-current assets
3,452
-
-
Accounts payable
-871
-641
-2,179
Accrued expenses and other current liabilities
-494
848
-9,945
Deferred revenue
0
0
-650
Other non-current liabilities
11
-236
15
Operating lease liabilities
-559
-544
-694
Net cash used in operating activities
-14,800
-7,218
-40,626
Cash divested in non-ox40 divestiture
-
0
5,215
Proceeds from disposal of property and equipment
-
0
0
Purchases of marketable securities
10,937
8,913
1,485
Maturities of marketable securities
10,497
7,549
2,250
Net cash used in investing activities
-440
-1,364
-4,450
Proceeds from term loan
-
0
15,000
Proceeds from exercise of stock options
35
0
45
Issuance costs in connection with reverse recapitalization
-
0
-5,338
Cash acquired in connection with reverse recapitalization
-
0
-54,631
Payment of issuance costs in connection with reverse recapitalization
3,279
-
-
Proceeds from common stock issued in pipe financing, net of issuance costs
-
0
71,130
Payment of deferred offering costs
0
-
-
Net cash provided by (used in) financing activities
-3,244
0
135,468
Effect of exchange rate changes on cash and cash equivalents
0
-48
652
Net change in cash and cash equivalents
-18,484
-8,630
91,044
Cash and cash equivalents at beginning of period
94,532
103,162
12,118
Cash and cash equivalents at end of period
76,048
94,532
103,162
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net change in cash
and cash...
-$18,484K
Stock-based compensation
expense
$876K
Amortization of right of
use-assets
$174K
Prepaid expenses and
other current assets
-$141K
Other non-current
liabilities
$11K
Proceeds from exercise of
stock options
$35K
Maturities of marketable
securities
$10,497K
Net cash used in
operating activities
-$14,800K
Net cash provided by
(used in) financing...
-$3,244K
Net cash used in
investing activities
-$440K
Canceled cashflow
$1,202K
Canceled cashflow
$35K
Canceled cashflow
$10,497K
Net loss
-$10,619K
Deposits and other
non-current assets
$3,452K
Accounts payable
-$871K
Payment of issuance
costs in connection...
$3,279K
Purchases of marketable
securities
$10,937K
Operating lease
liabilities
-$559K
Accrued expenses and
other current...
-$494K
Accretion of discounts on
marketable securities, net
$7K
Buy us a coffee